期刊
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
卷 5, 期 6, 页码 335-348出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756285612455367
关键词
Alzheimer's disease; biomarker; blood; cerebrospinal fluid; dementia
资金
- FP7 EU grant IMI-PHARMACOG [115009]
- FP7 EU grant NADINE [246513]
- FP7 EU grant PEPMIP [264699]
- PURE (Protein Research Unit Ruhr within Europe) from the State government of North Rhine-Westphalia
- Neuroallianz form the German Federal Ministry of Education and Research
Neurochemical biomarkers for diagnosing dementias are currently under intensive investigation and the field is rapidly expanding. The main protagonists and the best defined among them are cerebrospinal fluid levels of A beta 42, tau and its phosphorylated forms (p-tau). In addition, novel cerebrospinal fluid biomarkers are emerging and their multiparametric assessment seems most promising for increasing the accuracy in neurochemical dementia diagnostics. The combined assessment of A beta 42 and p-tau has recently shown value for diagnosing prodromal states of Alzheimer's dementia, that is, mild cognitive impairment. Disease-specific biomarkers for other degenerative dementias are still missing, but some progress has recently been made. As lumbar puncture is an additional burden for the patient, blood-based neurochemical biomarkers are definitely warranted and promising new discoveries have been made in this direction. These diagnostic developments have implicit therapeutic consequences and give rise to new requirements for future neurochemical dementia diagnostics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据